Pharma
-
European Commission approves first GLP-1 weight loss pill for obesity treatment
Novo Nordisk’s once-daily Wegovy pill becomes the first GLP-1 receptor agonist tablet approved in the European Union for weight management.…
Read More » -
Novartis to acquire Myricx Bio to strengthen next-generation cancer therapy pipeline
The UK biotechnology company’s novel antibody-drug conjugate platform and two preclinical cancer therapy candidates will expand Novartis’ oncology research portfolio.…
Read More » -
EU approves Enhertu as first tumour-agnostic HER2-targeted therapy for metastatic solid tumours
The approval allows the drug to be used across multiple HER2-positive cancers, regardless of where the tumour originated, for patients…
Read More » -
New treatment for alopecia areata in adults and adolescents moves closer to EU approval after CHMP recommendation
Positive opinion is based on Phase III trial results showing significant scalp hair regrowth, with a final European Commission decision…
Read More » -
Merck to acquire Bio-Techne in $11.3 billion deal to expand life sciences business
The proposed acquisition will strengthen Merck’s presence in areas including multi-omics, spatial biology and cell and gene therapy, subject to…
Read More » -
Biogen to acquire RayThera in deal worth up to $1 billion
The acquisition adds multiple immunology assets to Biogen’s pipeline, including a lead anti-inflammatory candidate expected to enter Phase 1 development…
Read More » -
FDA approves Utebzi, first oral carbapenem antibiotic for complicated urinary tract infections in adults
New oral treatment could help eligible patients receive care outside hospital settings instead of relying on intravenous antibiotics The US…
Read More » -
FDA approves first hyaluronic acid injectable to reduce horizontal neck lines
The U.S. Food and Drug Administration (FDA) has approved SKINVIVE by Juvéderm for reducing horizontal neck lines and improving neck…
Read More » -
KEYTRUDA-WELIREG combination wins FDA approval for high-risk kidney cancer after surgery
Approval is based on Phase III LITESPARK-022 trial results showing a 28% reduction in the risk of disease recurrence, metastasis…
Read More » -
CagriSema shows strong blood sugar and weight loss results in phase 3 diabetes trials
Novo Nordisk reported significant reductions in HbA1c and body weight with its investigational once-weekly therapy CagriSema across three phase 3…
Read More »
